{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:02:14Z","timestamp":1789549334951,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002378","name":"Faculty of Veterinary Medicine, Cairo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.lfs.2023.122245","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T02:16:17Z","timestamp":1699064177000},"page":"122245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Lactoferrin ameliorates carfilzomib-induced renal and pulmonary deficits: Insights to the inflammasome NLRP3\/NF-\u03baB and PI3K\/Akt\/GSK-3\u03b2\/MAPK axes"],"prefix":"10.1016","volume":"335","author":[{"given":"Christine N.","family":"Habib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa E.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla H.","family":"Anber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina Y.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lfs.2023.122245_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122245_bb0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","volume":"31","author":"H\u00e1jek","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.lfs.2023.122245_bb0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lfs.2023.122245_bb0020","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors Bortezomib and carfilzomib: a link to clinical adverse EventsNonproteasomal targets of proteasome inhibitors","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.lfs.2023.122245_bb0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.lfs.2023.122245_bb0030","first-page":"3281","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"6","key":"10.1016\/j.lfs.2023.122245_bb0035","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/1535-7163.MCT-12-0782","article-title":"Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple MyelomaUPR in multiple myeloma","volume":"12","author":"Vincenz","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.lfs.2023.122245_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-020-00381-4","article-title":"Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients","volume":"10","author":"Fotiou","year":"2020","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.lfs.2023.122245_bb0045","first-page":"1753","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013"},{"issue":"4","key":"10.1016\/j.lfs.2023.122245_bb0050","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211049300","article-title":"Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma","volume":"11","author":"Yang","year":"2021","journal-title":"Pulmonary Circulation"},{"issue":"3","key":"10.1016\/j.lfs.2023.122245_bb0055","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lfs.2023.122245_bb0060","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/15376516.2016.1236425","article-title":"Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-\u03baB and MAPK signaling in rats","volume":"26","author":"Imam","year":"2016","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.lfs.2023.122245_bb0065","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10787-018-0550-5","article-title":"Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF-\u03baB signaling pathway","volume":"27","author":"Al-Harbi","year":"2019","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.lfs.2023.122245_bb0070","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1038\/bcj.2015.112","article-title":"Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?","volume":"6","author":"Rosenthal","year":"2016","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.lfs.2023.122245_bb0075","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2215\/CJN.06100616","article-title":"Renal toxicities of novel agents used for treatment of multiple myeloma","volume":"12","author":"Wanchoo","year":"2017","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"14","key":"10.1016\/j.lfs.2023.122245_bb0080","first-page":"2817","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.lfs.2023.122245_bb0085","doi-asserted-by":"crossref","DOI":"10.1177\/10781552231190039","article-title":"Carfilzomib-induced life-threatening lung injury in refractory multiple myeloma","author":"Ghasoub","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.lfs.2023.122245_bb0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_107_20","article-title":"Severe right-sided heart failure and pulmonary hypertension with carfilzomib treatment in multiple myeloma","volume":"21","author":"Mathur","year":"2020","journal-title":"Heart Views: The Official Journal of the Gulf Heart Association"},{"issue":"1","key":"10.1016\/j.lfs.2023.122245_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13799","article-title":"Efficacy and safety of salvage therapy using carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study","volume":"172","author":"Muchtar","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.lfs.2023.122245_bb0100","article-title":"Etiology of pulmonary hypertension in multiple myeloma: a case series and literature review","volume":"206","author":"Desmarais","year":"2022","journal-title":"Respir. Med."},{"issue":"8","key":"10.1016\/j.lfs.2023.122245_bb0105","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00277-015-2392-1","article-title":"Fatal pulmonary hemorrhage after carfilzomib treatment in multiple myeloma","volume":"94","author":"Kwong","year":"2015","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.lfs.2023.122245_bb0110","first-page":"286","article-title":"Fatal pulmonary toxicity following carfilzomib administration","volume":"20","author":"Marschall","year":"2021"},{"issue":"1","key":"10.1016\/j.lfs.2023.122245_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-915","article-title":"Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring","volume":"14","author":"Chari","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2023.122245_bb0120","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1007\/s00018-005-5369-8","article-title":"Lactoferrin: multifunctional roles of lactoferrin: a critical overview","volume":"62","author":"Ward","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.lfs.2023.122245_bb0125","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1086\/596212","article-title":"Lactoferrin as a natural regimen for selective decontamination of the digestive tract: recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonates from pathogenic challenge in the gastrointestinal tract","volume":"199","author":"Yen","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lfs.2023.122245_bb0130","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00018-005-5373-z","article-title":"Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties","volume":"62","author":"Gifford","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.lfs.2023.122245_bb0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1389203719666180514150921","article-title":"Lactoferrin: major physiological functions and applications","volume":"20","author":"Hao","year":"2019","journal-title":"Curr. Protein Pept. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2023.122245_bb0140","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3164\/jcbn.11-100","article-title":"Bovine lactoferrin ameliorates ferric nitrilotriacetate-induced renal oxidative damage in rats","volume":"51","author":"Okazaki","year":"2012","journal-title":"J. Clin. Biochem. Nutr."},{"issue":"2","key":"10.1016\/j.lfs.2023.122245_bb0145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/ph16020192","article-title":"Potential of Lactoferrin in the treatment of lung diseases","volume":"16","author":"Kaczy\u0144ska","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lfs.2023.122245_bb0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40204-015-0037-z","article-title":"Assessment of lactoferrin-conjugated solid lipid nanoparticles for efficient targeting to the lung","volume":"4","author":"Shilpi","year":"2015","journal-title":"Progress in Biomaterials"},{"issue":"4","key":"10.1016\/j.lfs.2023.122245_bb0155","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.3168\/jds.2012-6153","article-title":"Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor","volume":"96","author":"Tung","year":"2013","journal-title":"J. Dairy Sci."},{"key":"10.1016\/j.lfs.2023.122245_bb0160","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s11307-019-01390-x","article-title":"Lactoferrin protects Hyperoxia-induced lung and kidney systemic inflammation in an in vivo imaging model of NF-\u03baB\/luciferase transgenic mice","volume":"22","author":"Yen","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.lfs.2023.122245_bb0165","series-title":"Theory and Practice of Histological Techniques","author":"Bancroft","year":"2013"},{"key":"10.1016\/j.lfs.2023.122245_bb0170","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for relapsed and refractory multiple myeloma","volume":"11","author":"Groen","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lfs.2023.122245_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211019612","article-title":"The role of carfilzomib in relapsed\/refractory multiple myeloma","volume":"12","author":"Yee","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.lfs.2023.122245_bb0180","doi-asserted-by":"crossref","first-page":"492A","DOI":"10.1016\/j.chest.2016.08.506","volume":"150","author":"Bhagavath","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.lfs.2023.122245_bb0185","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00277-020-04062-x","article-title":"Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials","volume":"99","author":"Ball","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lfs.2023.122245_bb0190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1292\/jvms.12-0154","article-title":"Protective effect of lactoferrin on cisplatin-induced nephrotoxicity in rats","volume":"75","author":"Kimoto","year":"2013","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.lfs.2023.122245_bb0195","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2023.122245_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108738","article-title":"Nose-to-brain delivery of chrysin transfersomal and composite vesicles in doxorubicin-induced cognitive impairment in rats: insights on formulation, oxidative stress and TLR4\/NF-kB\/NLRP3 pathways","volume":"197","author":"Ibrahim","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2023.122245_bb0205","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.lfs.2023.122245_bb0210","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2023.122245_bb0215","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.intimp.2018.11.023","article-title":"Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries","volume":"66","author":"Imam","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2023.122245_bb0220","article-title":"Ameliorative potential of Lactoferrin on methotrexate-induced nephrotoxicity in rat: a histological and Immunohistochemical study","volume":"0","author":"Elseady","year":"2021","journal-title":"Egypt. J. Histol."},{"key":"10.1016\/j.lfs.2023.122245_bb0225","doi-asserted-by":"crossref","first-page":"7383","DOI":"10.3168\/jds.2020-19232","article-title":"Inhibitory effects of lactoferrin on pulmonary inflammatory processes induced by lipopolysaccharide by modulating the TLR4-related pathway","volume":"104","author":"Li","year":"2021","journal-title":"J. Dairy Sci."},{"key":"10.1016\/j.lfs.2023.122245_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","author":"Cantley","year":"2002","journal-title":"Science."},{"key":"10.1016\/j.lfs.2023.122245_bb0235","first-page":"2534","article-title":"JNK\/PI3K\/Akt signaling pathway is involved in myocardial ischemia\/reperfusion injury in diabetic rats: effects of salvianolic acid A intervention","volume":"8","author":"Chen","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.lfs.2023.122245_bb0240","first-page":"5163","article-title":"Renoprotective effects of emodin against diabetic nephropathy in rat models are mediated via PI3K\/Akt\/GSK-3\u03b2 and bax\/caspase-3 signaling pathways","volume":"14","author":"Jing","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.lfs.2023.122245_bb0245","doi-asserted-by":"crossref","unstructured":"T. Noori, A. R. Dehpour, A. Sureda, S. Fakhri, E. Sobarzo-Sanchez, M.H. Farzaei, E. K\u00fcpeli Akkol, Z. Khodarahmi, S. Z. Hosseini, S. D. Alavi, S. Shirooie, The role of glycogen synthase kinase 3 beta in multiple sclerosis. Biomed. Pharmacother. 132 (2020) 110874, doi:https:\/\/doi.org\/10.1016\/j.biopha.2020.110874.","DOI":"10.1016\/j.biopha.2020.110874"},{"issue":"11","key":"10.1016\/j.lfs.2023.122245_bb0250","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/CIRCRESAHA.109.197996","article-title":"Role of glycogen synthase kinase-3\u03b2 in cardioprotection","volume":"104","author":"Juhaszova","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2023.122245_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117535","article-title":"Potential therapeutic antipsychotic effects of Naringin against ketamine-induced deficits in rats: involvement of Akt\/GSK-3\u03b2 and Wnt\/\u03b2-catenin signaling pathways","volume":"249","author":"George","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.lfs.2023.122245_bb0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.it.2009.09.007","article-title":"Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)","volume":"31","author":"Beurel","year":"2010","journal-title":"Trends Immunol."},{"key":"10.1016\/j.lfs.2023.122245_bb0265","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/930710","article-title":"GSK-3\u03b2: a bifunctional role in cell death pathways","volume":"2012","author":"Jacobs","year":"2012","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.lfs.2023.122245_bb0270","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1681\/ASN.2009080828","article-title":"GSK3\u03b2 promotes apoptosis after renal ischemic injury","volume":"21","author":"Wang","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.lfs.2023.122245_bb0275","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cyto.2010.10.009","article-title":"Glycogen synthase kinase 3: a point of convergence for the host inflammatory response","volume":"53","author":"Wang","year":"2010","journal-title":"Cytokine."},{"key":"10.1016\/j.lfs.2023.122245_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121528","article-title":"Lactoferrin alleviates cyclophosphamide induced-nephropathy through suppressing the orchestration between Wnt4\/\u03b2-catenin and ERK1\/2\/NF-\u03baB signaling and modulating klotho and Nrf2\/HO-1 pathway","volume":"319","author":"Mohamed","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2023.122245_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.633054","article-title":"GSK-3 inhibition modulates metalloproteases in a model of lung inflammation and fibrosis","volume":"8","author":"Cinetto","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.lfs.2023.122245_bb0290","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuropharm.2010.06.006","article-title":"Glycogen synthase kinase-3 and p38 MAPK are required for opioid-induced microglia apoptosis","volume":"59","author":"Xie","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2023.122245_bb0295","article-title":"Pramipexole and Lactoferrin ameliorate cyclophosphamide-induced haemorrhagic cystitis via targeting Sphk1\/S1P\/MAPK, TLR-4\/NF-\u03baB, and NLRP3\/caspase-1\/IL-1\u03b2 signalling pathways and modulating the Nrf2\/HO-1 pathway","volume":"112","author":"Baky","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2023.122245_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192316193","article-title":"Effects of curcumin and Lactoferrin to inhibit the growth and migration of prostatic cancer cells","volume":"19","author":"Costantini","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.lfs.2023.122245_bb0305","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2187696","article-title":"Bovine Lactoferrin induces cell death in human prostate Cancer cells","volume":"2022","author":"Rocha","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2023.122245_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26010205","article-title":"Lactoferrin: a glycoprotein involved in immunomodulation, anticancer, and antimicrobial processes","volume":"26","author":"Rasc\u00f3n-Cruz","year":"2021","journal-title":"Molecules."},{"key":"10.1016\/j.lfs.2023.122245_bb0315","first-page":"1","article-title":"Study on the therapeutic benefit on Lactoferrin in patients with colorectal cancer receiving chemotherapy","volume":"2014","author":"Moastafa","year":"2014","journal-title":"Int. Sch. Res. Not."},{"key":"10.1016\/j.lfs.2023.122245_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051362","article-title":"Lactoferrin and nanotechnology: the potential for Cancer treatment","volume":"15","author":"Tran","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.lfs.2023.122245_bb0325","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2217\/nnm-2020-0090","article-title":"Targeting cancer with lactoferrin nanoparticles: recent advances","volume":"15","author":"Kondapi","year":"2020","journal-title":"Nanomedicine."},{"issue":"3","key":"10.1016\/j.lfs.2023.122245_bb0330","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00066-011-0046-3","article-title":"Radiation-induced changes in breathing frequency and lung histology of C57BL\/6 J mice are time- and dose-dependent","volume":"188","author":"Eldh","year":"2012","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.lfs.2023.122245_bb0335","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00007890-198303000-00002","article-title":"An experimental model for assessment of renal recovery from warm ischemia","volume":"35","author":"Jablonski","year":"1983","journal-title":"Transplantation."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523008809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523008809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:11:48Z","timestamp":1758402708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320523008809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":67,"alternative-id":["S0024320523008809"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122245","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lactoferrin ameliorates carfilzomib-induced renal and pulmonary deficits: Insights to the inflammasome NLRP3\/NF-\u03baB and PI3K\/Akt\/GSK-3\u03b2\/MAPK axes","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122245"}}